Study guide

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management

Key Takeaways Explain This Topic AI

EuroSCORE II and STS risk models calculate predicted operative mortality based on patient, cardiac, and surgical factors; coronary angiographic dominance is right-sided in ~85% of patients (PDA arising from RCA), and significant disease is defined as >70% luminal diameter reduction, or >50% for left main coronary artery stenosis.

Aortic stenosis requires a 'slow, sinus, and full' hemodynamic state with preserved systemic vascular resistance to maintain coronary perfusion pressure, whereas aortic regurgitation benefits from 'fast, forward, and full' hemodynamics (heart rate 80-100 bpm) to shorten diastole and reduce regurgitant volume.

Cardiopulmonary bypass (CPB) mandates unfractionated heparin (300-400 IU/kg) targeting an Activated Clotting Time (ACT) > 400-480 seconds; heparin resistance secondary to antithrombin III deficiency is treated with fresh frozen plasma or ATIII concentrate, and protamine reversal (1 mg/100 IU heparin) carries risks of Type I hypotension, Type II anaphylaxis, or Type III catastrophic pulmonary hypertension.

Cardioplegia achieves electromechanical arrest in diastole via high-potassium depolarizing solutions (16-20 mmol/L K+), slashing myocardial oxygen consumption ( M V ˙ O 2 M\dot{V}\text{O}_2 M V ˙ O 2 ​ ) by ~90%; the intra-aortic balloon pump (IABP) augments coronary perfusion during diastolic inflation at the dicrotic notch and reduces left ventricular afterload during presystolic deflation.

Last updated: October 2026

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management

Cardiac anaesthesia demands a rigorous understanding of cardiovascular dynamics, extracorporeal technology, and myocardial preservation. Managing patients undergoing cardiac surgery requires reconciling severe structural lesions with the non-physiological states imposed by cardiopulmonary bypass (CPB).

1. Preoperative Evaluation and Risk Stratification in Cardiac Surgery

Preoperative assessment in cardiac surgical candidates quantifies functional reserve, identifies end-organ dysfunction, and stratifies perioperative morbidity and mortality using validated multivariable algorithms.

Operative Risk Prediction Models

Two major clinical risk scoring algorithms dominate contemporary cardiac surgical practice:

EuroSCORE II (European System for Cardiac Operative Risk Evaluation): Calculates predicted in-hospital mortality following cardiac surgery using patient-related factors (age, sex, renal impairment staged by creatinine clearance, extracardiac arteriopathy, poor mobility, prior cardiac surgery, chronic pulmonary disease, active endocarditis, critical preoperative state), cardiac factors (NYHA functional class, Canadian Cardiovascular Society [CCS] class 4 angina, left ventricular ejection fraction, recent myocardial infarction <90 days, pulmonary artery systolic pressure), and procedure-related factors (surgical urgency, elective vs urgent vs emergency vs salvage, weight of intervention [isolated CABG vs single non-CABG vs two procedures vs three or more procedures], and surgery on the thoracic aorta).

STS (Society of Thoracic Surgeons) Risk Model: Widely utilized internationally, calculating predicted 30-day mortality alongside specific morbidities: permanent stroke, prolonged mechanical ventilation (>24 hours), acute kidney injury requiring renal replacement therapy, deep sternal wound infection, and reoperation.

Coronary Angiogram Interpretation

Anaesthesiologists must systematically review coronary angiograms prior to surgery to anticipate regional ischemia and plan hemodynamic support:

Coronary Dominance: Determined by which coronary artery gives rise to the posterior descending artery (PDA) , which supplies the posterior third of the interventricular septum and the inferior wall of the left ventricle:

Right Dominant (~85%): PDA branches from the distal Right Coronary Artery (RCA).

Left Dominant (~10-15%): PDA branches from the Left Circumflex Artery (LCx).

Co-dominant (~5%): Posterior interventricular groove is supplied by branches from both the RCA and LCx.

Significance Criteria: Luminal diameter reduction ≥ 70 % \ge 70\% ≥ 70% is considered hemodynamically significant in epicardial vessels (Left Anterior Descending [LAD], LCx, RCA). For the Left Main Coronary Artery (LMCA) , luminal stenosis ≥ 50 % \ge 50\% ≥ 50% constitutes critical, life-threatening disease, predisposing to catastrophic global left ventricular ischemia during induction.

Fractional Flow Reserve (FFR): Invasive physiological assessment of coronary stenosis during pharmacological hyperemia (intravenous adenosine). An FFR ≤ 0.80 \le 0.80 ≤ 0.80 confirms functionally significant myocardial ischemia warranting revascularization.

2. Valvular Heart Disease Pathophysiology and Hemodynamic Goals

Anaesthetic induction and maintenance must be tailored to the specific mechanical and loading constraints of each valvular defect.

Valvular Lesion Primary Pathophysiology Heart Rate Rhythm Preload Afterload / SVR Inotropy

Aortic Stenosis (AS) Fixed LVOT obstruction; concentric LV hypertrophy; low compliance; elevated M V ˙ O 2 M\dot{V}\text{O}_2 M V ˙ O 2 ​ . Slow-Normal (60-70 bpm); avoid tachycardia and extreme bradycardia. Sinus Rhythm mandatory ; atrial kick provides 20-40% of LVEDV. Full / High ; stiff LV requires elevated filling pressures. Preserved / High ; maintain DBP to drive coronary perfusion ( C P P = D B P − L V E D P CPP = DBP - LVEDP CPP = D BP − L V E D P ). Maintain baseline; avoid excessive beta-agonism.

Aortic Regurgitation (AR) Diastolic volume overload; eccentric LV hypertrophy; wide pulse pressure; reduced DBP. Fast-Normal (80-100 bpm); shortens diastole, reducing regurgitant volume. Sinus preferred, but mild sinus tachycardia well tolerated. Full / Elevated ; maintains forward stroke volume despite backflow. Low / Reduced ; afterload reduction promotes forward systemic flow. Preserved; treat LV dysfunction promptly.

Mitral Stenosis (MS) Fixed inflow obstruction; elevated LAP; pulmonary hypertension; underfilled LV; RV strain. Slow (60-70 bpm); maximizes diastolic filling time across stenotic valve. Sinus Rhythm vital ; acute AF precipitously drops CO and triggers pulmonary edema. Carefully Maintained ; avoid hypovolemia and fluid overload. Normal ; maintain SVR to preserve organ perfusion. Maintain RV contractility; aggressively prevent RV failure.

Mitral Regurgitation (MR) Systolic volume overload into low-pressure LA; eccentric LV hypertrophy; overestimated EF. Normal-Fast (80-90 bpm); smaller LV chamber size reduces regurgitant orifice. Sinus rhythm beneficial; AF common due to chronic LA stretch. Normal-Full ; supports forward output without worsening LA hypertension. Low / Aggressively Reduced ; lowers resistance to aortic ejection over LA backflow. Maintain; inotropes and afterload reduction synergize.

Critical Clinical Distinctions:

Aortic Stenosis: Concentric hypertrophy shifts the pressure-volume loop upward and to the left. The thick, non-compliant ventricle relies heavily on the atrial kick. Acute loss of sinus rhythm (e.g. junctional rhythm or atrial fibrillation) triggers immediate, profound hypotension. Tachycardia dramatically curtails diastolic coronary perfusion time while escalating oxygen demand, inducing subendocardial ischemia. Vasodilators (such as nitroprusside or high-dose ACE inhibitors) are hazardous because fixed outflow obstruction prevents compensatory increases in stroke volume, causing catastrophic systemic and coronary hypoperfusion. Phenylephrine is the vasopressor of choice for maintaining perfusion pressure without inducing tachycardia.

Aortic Regurgitation: The regurgitant volume per beat is proportional to the duration of diastole ( t diastole t_{\text{diastole}} t diastole ​ ) and the transvalvular diastolic pressure gradient ( D B P − L V E D P DBP - LVEDP D BP − L V E D P ). Bradycardia prolongs diastole, causing massive ventricular over-distension, acute pulmonary venous congestion, and subendocardial ischemia from elevated wall tension. The management rule of thumb is "fast, forward, and full" .

3. Cardiopulmonary Bypass (CPB) Circuit Architecture

The CPB circuit mechanically substitutes for the functions of the heart and lungs, creating an extracorporeal loop that diverts venous blood, exchanges respiratory gases, modulates systemic temperature, and returns oxygenated blood to the arterial tree under controlled pressure. [ Systemic Veins (SVC / IVC) ]

  • |
  • (Venous Cannulae)
  • v
  • [ Venous Reservoir ] <--- (Cardiotomy Suction & Vent Blood)
  • |
  • v
  • [ Arterial Blood Pump ] ---> (Roller or Centrifugal)
  • |
  • v
  • [ Membrane Oxygenator ] <---> [ Heat Exchanger (Water Bath) ]
  • |
  • v
  • [ Arterial Line Filter ] (20-40 micron screen + Bubble Trap)
  • |
  • (Arterial Cannula)
  • v
  • [ Ascending Aorta ]
  • Circuit Components and Engineering Specifications

Venous Cannulation and Drainage:

Two-Stage Single Atriocaval Cannula: Inserted via the right atrial appendage into the inferior vena cava (IVC); drains IVC through the distal basket and superior vena cava (SVC) / right atrium via proximal side-holes. Standard for isolated CABG and aortic valve procedures where the right heart is not opened.

Bicaval Cannulation: Separate cannulae placed directly into the SVC and IVC, secured with tourniquets (caval snares / Rumel tourniquets). Mandatory for procedures opening the right heart (tricuspid/mitral valve surgery, ASD/VSD repair) to isolate the right heart chambers completely from venous return.

Drainage Mechanics: Primarily relies on siphon gravity drainage (reservoir positioned 40-70 cm below the patient's right atrium) or Vacuum-Assisted Venous Drainage (VAVD; applying negative pressure of − 20 to − 40 mmHg -20\text{ to }-40\text{ mmHg} − 20 to − 40 mmHg to a sealed reservoir to facilitate drainage through smaller cannulae in minimally invasive surgery).

Venous Reservoir: Collects systemic venous return, acts as a compliant volume buffer, and houses a coarse mesh defoamer/filter to eliminate gross air bubbles before pumping.

Arterial Blood Pumps:

Roller Pumps: Positive displacement pumps utilizing rotating rollers that compress medical-grade silicone tubing against a semicircular raceway. Output is strictly dependent on roller RPM and tubing diameter, independent of afterload or preload. Hazards: True occlusion can generate extreme pressures ( > 1000 mmHg >1000\text{ mmHg} > 1000 mmHg ) if downstream obstruction occurs, risking line rupture or spallation of microparticles from tube wear. Inadvertent pumping of gross air if the reservoir runs dry.

Centrifugal Pumps: Non-occlusive magnetically coupled impellers or nested cones rotating at high speed (2000-3500 RPM). Blood is propelled by kinetic energy and centrifugal force. Flow is non-obligate and directly sensitive to both preload and afterload (if downstream pressure spikes, flow decreases to zero without line rupture). Hazards: Backward flow (retrograde siphonage) into the pump if the pump stops rotating while the arterial line is un-clamped.

Membrane Oxygenators: Contemporary oxygenators utilize hollow-fiber microporous polypropylene or polymethylpentene membranes. Venous blood flows over the external surface of microscopic hollow fibers while sweep gas ( O 2 / Air O_2 / \text{Air} O 2 ​ / Air mixture) flows through the fiber lumina. Gas transfer occurs via passive diffusion across microscopic pores:

Oxygenation ( P a O 2 P_a\text{O}_2 P a ​ O 2 ​ ) is controlled by adjusting the fraction of delivered oxygen ( F i O 2 F_i\text{O}_2 F i ​ O 2 ​ ) in the sweep gas.

Carbon dioxide elimination ( P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ ) is controlled by altering the sweep gas flow rate (increasing sweep flow flushes C O 2 CO_2 C O 2 ​ from the gas boundary layer, enhancing clearance).

Heat Exchanger: Integrated into the oxygenator; utilizes countercurrent warm or cold water circulating through stainless steel or polyurethane tubes to control blood temperature.

Arterial Line Filter: Screen filter with a pore size of 20 to 40 μ m \mu\text{m} μ m placed between the oxygenator and the patient. It incorporates a one-way continuous purge line to capture gaseous microemboli, fat globules, and aggregate cellular debris before blood reaches the ascending aorta.

4. Priming Solution and Hemodilution Mechanics

The extracorporeal circuit must be primed with liquid to eliminate all air before connecting to the vasculature. The priming volume typically ranges from 1100 to 1500 mL of balanced crystalloid solution (e.g. Plasma-Lyte, Ringer's acetate/lactate), frequently supplemented with:

Mannitol (0.5 g/kg or 12.5-25 g): Acts as an osmotic diuretic, scavenges oxygen-derived free radicals, and supports renal tubular patency during low-pressure bypass.

Heparin (5,000 - 10,000 IU): Prevents thrombotic activation on foreign circuit surfaces upon initial blood contact.

Sodium Bicarbonate: Buffers prime solution acidosis.

Albumin 20% or Synthetic Colloids: Increases prime oncotic pressure to limit tissue edema.

Acute Normovolemic Hemodilution on CPB

When the patient's blood mixes with the crystalloid prime, acute hemodilution occurs. The resulting hematocrit ( H c t CPB Hct_{\text{CPB}} Hc t CPB ​ ) can be estimated by: H c t CPB = H c t patient × E B V E B V + V prime Hct_{\text{CPB}} = \frac{Hct_{\text{patient}} \times EBV}{EBV + V_{\text{prime}}} Hc t CPB ​ = EB V + V prime ​ Hc t patient ​ × EB V ​ where E B V EBV EB V is the patient's estimated blood volume (~ 70 mL/kg 70\text{ mL/kg} 70 mL/kg in males, ~ 65 mL/kg 65\text{ mL/kg} 65 mL/kg in females) and V prime V_{\text{prime}} V prime ​ is the circuit prime volume.

Target Hematocrit: Maintained between 22% and 25% (hemoglobin ~7.0-8.5 g/dL) during hypothermic CPB.

Physiological Rationale: Moderate hemodilution offsets the marked increase in blood viscosity induced by hypothermia (blood viscosity increases by ~2% for every 1°C fall in temperature), preserving microcirculatory capillary perfusion and preventing rheological stasis. However, excessive hemodilution ( H c t < 20 % Hct < 20\% Hc t < 20% ) compromises systemic oxygen delivery ( D ˙ O 2 \dot{D}\text{O}_2 D ˙ O 2 ​ ), impairs renal medullary oxygenation, and correlates with increased rates of perioperative acute kidney injury and stroke.

5. Anticoagulation for CPB, Heparin Resistance, and Protamine Reversal

Blood contact with the massive foreign surface area of the CPB circuit triggers immediate, catastrophic activation of the intrinsic coagulation pathway, contact system (Factor XII/kallikrein), and platelets. Flawless anticoagulation is mandatory.

Unfractionated Heparin (UFH) Protocol

Dose: 300 to 400 IU/kg administered via central venous catheter or directly into the right atrium by the surgeon.

Mechanism: Binds reversibly to antithrombin III (ATIII) via a specific high-affinity pentasaccharide sequence. This produces an allosteric conformational change that accelerates ATIII-mediated inactivation of thrombin (Factor IIa), Factor Xa, and Factors IXa, XIa, and XIIa by over 1,000-fold.

Monitoring with Activated Clotting Time (ACT):

Baseline ACT is measured prior to heparin administration (normal baseline: 90-130 seconds).

Measurements utilize Kaolin (clay activator) or Celite (diatomaceous earth activator) cartridges.

Target ACT for CPB: Must exceed 400 to 480 seconds prior to cannulation of the aorta and throughout the bypass run.

ACT must be checked every 30 to 45 minutes on bypass; supplemental heparin (3,000-5,000 IU) is administered if ACT falls below 480 seconds.

Heparin Resistance

Defined as the inability to achieve an ACT ≥ 400 – 480 seconds \ge 400\text{--}480\text{ seconds} ≥ 400 – 480 seconds despite the administration of a full weight-based heparin dose ( > 400 − 500 IU/kg >400-500\text{ IU/kg} > 400 − 500 IU/kg ).

Primary Etiology: Congenital or acquired Antithrombin III Deficiency . Acquired ATIII deficiency is exceedingly common in patients receiving preoperative unfractionated or low-molecular-weight heparin (which depletes ATIII stores), patients with acute coronary syndrome, active infective endocarditis, sepsis, or liver cirrhosis.

Management:

Administer a second supplemental dose of heparin (5,000-10,000 IU).

If ACT remains sub-therapeutic, administer Antithrombin III Concentrate (recombinant or human plasma-derived, 1,000-2,000 IU IV) or Fresh Frozen Plasma (FFP) (2 to 4 units; each unit contains ~1 IU/mL of functional ATIII).

Protamine Reversal and Adverse Reactions

Upon complete cessation of CPB and stable decannulation, heparin is reversed with Protamine Sulfate , a strongly basic, low-molecular-weight polycationic protein derived from salmon sperm. Protamine binds ionically to strongly acidic, polyanionic heparin, creating a stable, inactive neutral salt precipitate that eliminates anticoagulant activity.

Dosing: 1 mg of protamine neutralizes approximately 100 IU of active circulating heparin (titrated based on time elapsed since heparinization, typically 0.6-0.8 mg per 100 IU initial dose if >1-2 hours have elapsed). [ PROTAMINE ADVERSE REACTIONS ]

  • |
  • +-------------------------------+-------------------------------+
  • | | |
  • [ Type I: Rapid Injection ] [ Type II: Anaphylaxis ] [ Type III: Pulmonary HTN ]
  • Non-immunological histamine - IgE-mediated anaphylaxis - Complement-mediated C5a
  • & bradykinin release or anaphylactoid thromboxane A2 release
  • Peripheral vasodilation - Bronchospasm, flushing, - Severe pulmonary vasoconstriction
  • Transient hypotension angioedema, shock - RV failure & acute low output
  • Prevention: Slow IV over - Risk: NPH insulin, fish - Treatment: Stop protamine, inotropes,
  • 10-15 minutes allergy, post-vasectomy pulmonary vasodilators, resume CPB

Reaction Class Primary Mechanism Clinical Presentation High-Risk Groups Prevention & Management

Type I (Hypotension) Rapid infusion rate triggering non-immunological peripheral histamine and bradykinin release. Systemic vasodilation, drop in SVR, transient arterial hypotension, preserved or elevated cardiac index. Rapid bolus administration (<5 minutes). Administer slowly over 10 to 15 minutes via peripheral vein or central line. Responsive to IV fluid bolus and phenylephrine/norepinephrine.

Type II (Anaphylactic / Anaphylactoid) Type IIa: IgE-mediated true anaphylaxis. Type IIb: Non-IgE-mediated mast cell/basophil activation. Type IIc: Non-cardiogenic pulmonary edema. Acute cardiovascular collapse, cutaneous erythema, bronchospasm, elevated peak airway pressures, facial angioedema. Prior exposure to NPH insulin (contains protamine); fish/salmon allergy ; prior vasectomy (anti-sperm antibodies cross-react with protamine). Pretreatment with antihistamines/steroids in high-risk patients. Treat with epinephrine ( 10 − 100 μ g 10-100\;\mu\text{g} 10 − 100 μ g boluses), IV fluids, bronchodilators, hydrocortisone.

Type III (Catastrophic Pulmonary HTN) Heparin-protamine complexes activate classical complement pathway (C5a), activating pulmonary intravascular macrophages to release Thromboxane A 2 A_2 A 2 ​ and endothelin. Sudden massive spike in Pulmonary Artery Pressure (PAP), acute right ventricular dilation and failure, severe bronchospasm, arterial hypotension, drop in LV preload. High heparin-protamine complex burden; rapid injection. Stop protamine infusion immediately . Administer inotropic support for RV (epinephrine, milrinone), inhaled pulmonary vasodilators (prostacyclin, nitric oxide). If RV refractory collapse ensues, re-heparinize and return immediately to CPB .

6. Myocardial Protection and Cardioplegia Delivery

Surgical repair of intracardiac structures necessitates a quiet, bloodless, flaccid heart, achieved by cross-clamping the ascending aorta. Without protection, normothermic myocardial ischemia causes irreversible necrosis within 15 to 20 minutes.

Biophysical Principles of Cardioplegic Arrest

Mechanisms of Metabolic Arrest: Infusion of a hyperkalemic cardioplegic solution into the coronary circulation rapidly elevates extracellular potassium ( [ K + ] e = 16 – 20 mmol/L [K^+]_e = 16\text{--}20\text{ mmol/L} [ K + ] e ​ = 16 – 20 mmol/L ). According to the Nernst equation: E K = R T F ln ⁡ ( [ K + ] e [ K + ] i ) E_K = \frac{RT}{F} \ln \left( \frac{[K^+]_e}{[K^+]_i} \right) E K ​ = F RT ​ ln ( [ K + ] i ​ [ K + ] e ​ ​ ) Elevated extracellular potassium depolarizes the resting membrane potential of cardiomyocytes from − 90 mV -90\text{ mV} − 90 mV toward approximately − 50 mV -50\text{ mV} − 50 mV . At this partially depolarized voltage, fast voltage-gated sodium channels are permanently inactivated, blocking Phase 0 depolarization and arresting electrical conduction and mechanical contraction in diastole .

Metabolic Sparing: Halting mechanical electromechanical work cuts myocardial oxygen consumption ( M V ˙ O 2 M\dot{V}\text{O}_2 M V ˙ O 2 ​ ) by ~90% . Concomitant myocardial cooling to 4°C to 10°C reduces basal metabolic oxygen requirements by an additional factor of 2 for every 10°C drop ( Q 10 ≈ 2 Q_{10} \approx 2 Q 10 ​ ≈ 2 ), lowering ischemic M V ˙ O 2 M\dot{V}\text{O}_2 M V ˙ O 2 ​ to < 5 % <5\% < 5% of baseline normothermic contracting levels.

Cardioplegia Formulations and Delivery Modalities

Cold Crystalloid Cardioplegia (e.g. St. Thomas' Hospital Solution, Bretschneider/Custodiol, Del Nido): Crystalloid carrier containing balanced electrolytes, high potassium, magnesium (stabilizes membrane), procaine or lidocaine (sodium-channel blockade), and buffers. Del Nido cardioplegia incorporates lidocaine and mannitol, allowing single-dose administration providing 60 to 90 minutes of safe arrest.

Cold Blood Cardioplegia (e.g. 4:1 or 8:1 Blood-to-Crystalloid): Delivers autologous blood mixed with hyperkalemic crystalloid. Advantages include physiological oxygen-carrying capacity (via hemoglobin), endogenous buffering capacity (via histidine residues on hemoglobin and plasma proteins), and physiological oncotic pressure.

Warm Blood Cardioplegia ("Hot Shot"): A warm, substrate-enriched blood infusion (normokalemic, supplemented with aspartate/glutamate) administered immediately prior to aortic cross-clamp removal to replenish myocardial ATP and accelerate functional recovery upon reperfusion.

Delivery Routes:

Antegrade Cardioplegia: Administered into the aortic root proximal to the cross-clamp or directly into coronary ostia via handheld cannulae. Relies on an intact aortic valve; ineffective in severe aortic regurgitation , where fluid flows directly into the LV, causing severe LV distension and zero coronary delivery.

Retrograde Cardioplegia: Cannula placed into the coronary sinus via the right atrium; flows backwards through the cardiac venous system into coronary capillary beds. Essential in severe aortic regurgitation or high-grade multivessel coronary artery occlusions that prevent antegrade flow.

7. Systemic Hypothermia and Circulatory Arrest

Therapeutic hypothermia reduces global cerebral and systemic metabolic rate, extending the safe window of ischemic tissue viability.

Temperature Categories and Circulatory Arrest

Mild Hypothermia: 32°C to 35°C (standard for routine CABG and valve surgery).

Moderate Hypothermia: 28°C to 32°C (used for complex resections or mitral repairs).

Deep Hypothermic Circulatory Arrest (DHCA): Core temperature cooled to < 20 – 24 °C <20\text{--}24\text{°C} < 20 – 24 °C (typically 18°C). Used for complex aortic arch reconstruction (e.g. type A aortic dissection, elephant trunk procedure) where placement of an aortic cross-clamp is anatomically impossible. At 18°C, the cerebral metabolic rate ( C M R O 2 CMRO_2 CMR O 2 ​ ) is reduced to ~18-20% of baseline, permitting safe total circulatory arrest for 30 to 40 minutes without gross neurological deficit.

Adjunctive Neuroprotection during DHCA:

Topical craniocervical hypothermia (ice packed around head).

Pharmacological metabolic suppression (propofol, thiopental) to achieve electroencephalographic (EEG) burst suppression.

Selective Antegrade Cerebral Perfusion (SACP): Cannulation of the right axillary / subclavian artery or brachiocephalic artery, perfusing the brain with cold blood (10-15 mL/kg/min; line pressure 40-70 mmHg) during distal arch reconstruction.

Retrograde Cerebral Perfusion (RCP): Infusion of cold oxygenated blood retrogradely through the superior vena cava cannula (pressure maintained < 25 mmHg <25\text{ mmHg} < 25 mmHg to prevent cerebral edema).

Temperature-Corrected Acid-Base Management on CPB

Strategy Mechanism pH & P CO 2 P\text{CO}_2 P CO 2 ​ Regulation Cerebral Autoregulation Clinical Application

Alpha-Stat Blood gas sample is warmed to 37°C in the analyzer and NOT corrected for the patient's actual hypothermic temperature. Maintains constant ionization state of imidazole rings on histidine proteins (alpha neutrality). Intracellular electrochemical neutrality is preserved. Preserves normal cerebral blood flow autoregulation; flow remains strictly coupled to cerebral metabolism. Standard of care in adult cardiac surgery . Reduces cerebral microembolic load by preventing luxury cerebral hyperperfusion.

pH-Stat Blood gas values are corrected for the patient's actual hypothermic body temperature ; C O 2 CO_2 C O 2 ​ is deliberately added to the sweep gas. Maintains measured p H pH p H at 7.40 and P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ at 40 mmHg at the patient's hypothermic temperature. At lower temperatures, gas solubility increases, so adding C O 2 CO_2 C O 2 ​ causes relative hypercapnia. Hypercapnia abolishes cerebral autoregulation and induces profound cerebral vasodilation, producing pressure-passive, maximal cerebral blood flow. Standard of care in paediatric cardiac surgery and during the cooling phase of DHCA. Ensures rapid, uniform brain cooling before circulatory arrest.

8. Systematic Weaning from Cardiopulmonary Bypass

Separation from CPB transfers the circulatory workload back from the extracorporeal machine to the patient's heart and lungs. It must follow a structured, multi-system checklist.

The "WARM & STEADY" Weaning Protocol

W - Warm: Patient re-warmed to target core (bladder/rectal) temperature ≥ 36.5 °C \ge 36.5\text{°C} ≥ 36.5 °C and nasopharyngeal temperature ≤ 37.5 °C \le 37.5\text{°C} ≤ 37.5 °C (avoid hyperthermic cerebral injury). Peripheral temperature > 35 °C >35\text{°C} > 35 °C to ensure absence of severe peripheral vasoconstriction.

A - Air Cleared: Thorough de-airing of left-sided cardiac chambers (LA, LV, aortic root vent) verified by transesophageal echocardiography (TEE) under surgical agitation, Valsalva ventilation maneuvers, and steep Trendelenburg positioning.

R - Rhythm: Normal sinus rhythm, rate 80 to 100 bpm . Ventricular pacing, AV sequential epicardial pacing, or pharmacological cardioversion/defibrillation initiated if bradycardia, heart block, or tachyarrhythmias persist.

M - Metabolic & Electrolytes: Arterial blood gas confirmation: K + 4.0 − 5.0 mmol/L K^+ 4.0-5.0\text{ mmol/L} K + 4.0 − 5.0 mmol/L , ionized calcium ( i C a 2 + iCa^{2+} i C a 2 + ) > 1.0 − 1.1 mmol/L >1.0-1.1\text{ mmol/L} > 1.0 − 1.1 mmol/L , hematocrit > 22 − 25 % >22-25\% > 22 − 25% , p H 7.35 − 7.45 pH 7.35-7.45 p H 7.35 − 7.45 , base deficit < − 3 mmol/L < -3\text{ mmol/L} < − 3 mmol/L , lactate clearing.

S - Stable Ventilation: Mechanical ventilation re-instituted with 100% O 2 O_2 O 2 ​ , tidal volumes 6-8 mL/kg, PEEP 5 cmH 2 _2 2 ​ O. Lungs visually inspected for symmetrical bilateral inflation and expansion.

T - Tone & Inotropic Support: Baseline inotropic/vasopressor infusions established (e.g. norepinephrine for vasoplegic low SVR, milrinone or epinephrine for biventricular systolic failure, vasopressin for refractory vasoplegia).

E - Echocardiography: TEE evaluation of biventricular loading and function: global and regional LV systolic performance, RV fractional area change (FAC), patent coronary graft flows, competence of reconstructed valves, absence of dynamic LVOT obstruction.

A - Access & Calibration: Arterial line zeroed at the phlebostatic axis (or circle of Willis); CVP and pulmonary artery catheters transduced and calibrated.

D - Drainage Clamped: Perfusionist slowly clamps the venous drainage line, allowing ventricular chambers to fill with blood from the reservoir. Pump output is progressively reduced from full flow (100%) to partial flow (75%, 50%, 25%) while systemic blood pressure and filling pressures (CVP, PCWP, or direct LA line) are observed.

Y - You are Off! Flow terminated. Once hemodynamic stability is documented over several minutes, the venous cannula is removed, followed by the arterial cannula, and slow protamine administration begins.

9. Intra-Aortic Balloon Pump (IABP) Counterpulsation

The IABP is a temporary mechanical circulatory support device positioned percutaneously via the femoral artery into the descending thoracic aorta. Its tip sits 1 to 2 cm distal to the origin of the left subclavian artery , positioned above the renal artery branches. [ Aortic Pressure Waveform with IABP 1:2 ]

  • Pressure
  • ^ Augmented Diastolic
  • | Peak (PDP)
  • | / \
  • | Normal / \ Assisted
  • | Systole / \ Systole
  • | / \ / \ / \
  • | / \ Dicrotic / \ / \
  • | / \ Notch / \ / \
  • | / \ __ / \ / \
  • | / \/ \ / \ / \
  • |/ v \___/ \___
  • +--------------------------------------------------------> Time
  • ^ ^
  • Inflation Deflation
  • (at Dicrotic Notch) (before Systole)
  • Physiological Principles of Counterpulsation

Diastolic Inflation (Augmentation):

Timing: Rapid inflation with helium gas occurs precisely at the dicrotic notch of the aortic pressure waveform (marking aortic valve closure and the onset of diastole).

Hemodynamic Consequence: Displaces blood retrograde toward the aortic root, significantly increasing diastolic aortic root pressure (Peak Diastolic Pressure [PDP]). Because coronary blood flow occurs almost exclusively during diastole, this dramatically enhances Coronary Perfusion Pressure ( C P P = D B P − L V E D P CPP = DBP - LVEDP CPP = D BP − L V E D P ) and oxygen delivery to the myocardium.

Presystolic Deflation (Afterload Reduction):

Timing: Deflates rapidly immediately before ventricular systole (during the isovolumetric contraction phase, just prior to opening of the aortic valve).

Hemodynamic Consequence: The sudden evacuation of balloon volume creates a localized vacuum, dropping aortic end-diastolic pressure (Reduced Aortic End-Diastolic Pressure [BAEDP]). The left ventricle ejects against substantially lower vascular impedance, reducing LV peak systolic pressure, ventricular wall stress, and myocardial oxygen demand ( M V ˙ O 2 M\dot{V}\text{O}_2 M V ˙ O 2 ​ ), while augmenting stroke volume and cardiac output by 15% to 20% .

Synchronization, Triggers, and Contraindications

Triggers: Electrocardiographic R-wave (most common; balloon deflates on R-wave detection and inflates at the middle of the T-wave) or arterial pressure waveform tracking (inflates at the dicrotic notch and deflates at the end-diastolic upstroke).

Absolute Contraindications:

Moderate-to-Severe Aortic Regurgitation: Diastolic balloon inflation forcefully directs blood retrogradely through the incompetent aortic valve into the LV, producing catastrophic acute LV distension, pulmonary edema, and zero augmentation.

Aortic Dissection: Risk of balloon placement into the false lumen or propagating the intimal flap.

Severe Thoracic Aortic Aneurysm: Risk of rupture.

Relative Contraindications: Severe peripheral vascular disease (iliofemoral atherosclerosis, risk of limb ischemia), descending thoracic aortic stents, uncontrolled coagulopathy.